达安基因(002030) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥306,117,783.48, representing a decrease of 88.49% compared to the same period last year[6]. - The net profit attributable to shareholders was a loss of ¥50,160,960.00, down 103.81% year-on-year[6]. - Operating revenue for the first nine months of 2023 was CNY 842,336,232.83, a decrease of 90.98% compared to CNY 9,335,814,909.05 in the same period of 2022[13]. - The net profit attributable to shareholders of the parent company was CNY 352,594,428.71, reflecting a 92.82% decline from CNY 4,910,843,522.84 in the previous year[14]. - Net profit for the current period is ¥346,103,079.16, compared to ¥4,924,221,013.32 in the previous period, reflecting a decrease of approximately 93%[41]. - The company did not report any net profit for the period[67]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥284,229,944.43, reflecting a decline of 90.12% compared to the previous year[6]. - The company reported a net cash flow from investment activities of ¥414,763,431.21, a significant improvement compared to a loss of ¥1,275,410,454.71 in the same period last year[6]. - The company received cash from investment activities totaling ¥2,174,711,968.65, an increase from ¥1,551,671,841.27 in the previous year[6]. - The company’s cash outflow from investment activities was ¥1,759,948,537.44, down from ¥2,827,082,295.98 year-on-year[6]. - Net cash flow from operating activities was ¥2,594,203,731.39, down from ¥7,507,873,587.22, indicating a decrease of approximately 65.4%[67]. - The company reported a net cash outflow from financing activities of ¥2,295,287,752.57, compared to an outflow of ¥1,789,964,553.13 in the previous period, representing an increase in cash outflow of about 28.2%[70]. Assets and Liabilities - Total assets at the end of the reporting period were ¥11,310,013,290.86, a decrease of 23.36% from the end of the previous year[8]. - The total assets of the company decreased from ¥8,768,965,309.92 at the beginning of the year to ¥5,038,513,320.61 by the end of the reporting period[34]. - The company's total liabilities decreased to ¥1,864,144,034.96 from ¥3,141,165,451.71, a reduction of about 40.7%[61]. - The company’s total liabilities decreased from ¥8,768,965,309.92 to ¥5,038,513,320.61 during the reporting period[34]. - The total equity attributable to shareholders decreased to ¥9,137,395,440.31 from ¥11,301,118,032.72, reflecting a decline of approximately 19.2%[61]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 173,918, with significant holdings by state-owned entities[15]. - The basic earnings per share for the reporting period was -¥0.0357, a decline of 103.81% year-on-year[6]. - Basic earnings per share for the current period is ¥0.2512, down from ¥3.4991 in the previous period, a decline of about 93%[42]. Operational Costs and Expenses - Gross profit margin decreased significantly due to a reduction in sales volume, with operating costs dropping to CNY 380,716,762.30, down 84.04% from CNY 2,385,604,623.18[13]. - Total operating costs for the current period are ¥822,995,285.90, down from ¥3,573,962,390.92 in the previous period, indicating a reduction of about 77%[39]. - Research and development expenses were CNY 222,724,481.01, down 48.38% from CNY 431,499,051.61, primarily due to changes in personnel structure[13]. - The company’s financial expenses improved by 31.65%, with a reported financial cost of -CNY 61,333,256.01, mainly due to reduced interest income from time deposits[13]. Other Financial Metrics - The company experienced a 100.14% decline in investment income, reporting a loss of CNY 334,952.78 compared to a gain of CNY 240,889,914.17 in the previous year[14]. - The company reported a significant increase in fair value changes, with a gain of ¥403,291,564.96 compared to a loss of ¥38,673,594.26 in the previous period[41]. - The company recorded a loss of ¥35,551,684.70 from fair value changes of other non-current financial assets[22]. - The company received government subsidies totaling ¥71,191,845.05 from the beginning of the year to the end of the reporting period[22].